Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07069556

ColoSense Post-Approval Study

The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of ColoSense.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Decentralized Study

St Louis, Missouri, 63146, United States

Location status: Recruiting

Location contact

Erica K Barnell, MD PhD

CONTACT

[email protected]

314-887-7777

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is male or female, ≥45 years of age (subjects aged 18-45 can be enrolled onto the clinical trial but are not eligible for primary endpoint analysis)
  • Subject is able to understand the study procedures, and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a HIPAA medical release form
  • Subject is able and willing to provide stool samples within the 120 days prior to a colonoscopy procedure
  • Subject is able and willing to undergo a colonoscopy after providing a stool sample

Exclusion criteria

  • Subject had any precancerous findings on most recent colonoscopy. This does not include benign, and/or hyperplastic polyps of any size
  • Subject has a history or diagnosis of colorectal cancer
  • Subject has a history of aerodigestive tract cancer
  • Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals:
  • Fecal occult blood test or fecal immunochemical test within the previous twelve (12) months
  • FIT-DNA test within the previous 36 months
  • Subject has had a colonoscopy in the previous nine (9) years.
  • Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease
  • Indication for colonoscopy was due to overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)
  • Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:
  • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease
  • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP)
  • Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" of "Lynch Syndrome")
  • Other hereditary cancer syndromes including but are not limited to:
  • Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome
  • Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis
  • Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis

Treatment and study plan

ColoSense

Device

multi-target stool RNA test

Primary outcomes

  1. CRC Sensitivity

    Time frame: Through study completion, an average of 5 years.

    ColoSense sensitivity for subjects with colorectal cancer (CRC), which is the percentage of individuals with a diagnosis of CRC that were detected as positive by the ColoSense test.

  2. AA Sensitivity

    Time frame: Through study completion, an average of 5 years.

    ColoSense sensitivity for subjects with advanced adenomas (AA), which is the percentage of individuals with a diagnosis of AA that were detected as positive by the ColoSense test.

  3. SPL Sensitivity

    Time frame: Through study completion, an average of 5 years.

    ColoSense sensitivity for subjects with serrated precancerous lesions (SPL), which is the percentage of individuals with a diagnosis of SPL that were detected as positive by the ColoSense test.

  4. NEG Specificity

    Time frame: Through study completion, an average of 5 years.

    ColoSense specificity for subjects with negative findings, which is the percentage of individuals with a diagnosis of negative findings that were detected as negative by the ColoSense test.

Study contacts

Contact information is provided by the study sponsor or research team.

Erica K Barnell, MD PhD

CONTACT

[email protected]

314-887-7777

Sponsors and collaborators

Lead sponsor

Geneoscopy, Inc.

Industry

Registry information

Official study title

ColoSense Post Approval Study

Important dates

Study start
2025
Primary completion
2028
Study completion
2030
First posted
Jul 16, 2025
Registry last updated
Nov 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.